Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides

被引:177
作者
Kang, HM
DeLong, R
Fisher, MH
Juliano, RL [1 ]
机构
[1] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA
[2] Louisberg Coll, Dept Biol, Louisberg, NC USA
关键词
antisense; cell penetrating peptide; oligonucleotide; PAMAM dendrimer; siRNA; Tat;
D O I
10.1007/s11095-005-8330-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. PAMAM G5 dendrimer (P) was conjugated to Tat peptide (T), a cell penetrating peptide, in search of an efficient cellular delivery vehicle for antisense and siRNA oligonucleotides. Methods. PAMAM G5 dendrimer was reacted with 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, sulfosuccinimidyl ester, sodium salt (BODIPY) for visualization to yield the conjugate BP. Bifunctional sulfosuccinimidyl 6-[alpha-methyl-alpha-(2-pyridyldithio)toluamido]hexanoate (sulfo-LC-SMPT) was then used to conjugate primary amino groups of BP to cysteine derivatized Tat peptide to give the designed conjugate, BPT. This conjugate was complexed with antisense and siRNA oligonucleotides designed to inhibit MDR1 gene expression. NIH 3T3 MDR cells were used for the evaluation of biological activity of the conjugate. Results. Both antisense and siRNA readily formed complexes with the synthesized BPT, introduced into NIH 3T3 MDR cells, and primarily accumulated in intracellular vesicles. MDR1 gene expression was partially inhibited by the antisense-BPT complex and weakly inhibited by the siRNA-BPT complex when both were tested at nontoxic levels of dendrimer. Conjugation with Tat peptide did not improve the delivery efficiency of the dendrimer. Conclusions. Dendrimer-oligonucleotide complexes were moderately effective for delivery of antisense and only poorly effective for delivery of siRNA. Conjugation of the dendrimer with the Tat cell penetrating peptide failed to further enhance the effectiveness of the dendrimer.
引用
收藏
页码:2099 / 2106
页数:8
相关论文
共 24 条
[1]  
Alahari SK, 1998, J PHARMACOL EXP THER, V286, P419
[2]   P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[3]   Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates [J].
Astriab-Fisher, A ;
Sergueev, DS ;
Fisher, M ;
Shaw, BR ;
Juliano, RL .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (01) :83-90
[4]   Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles [J].
Braun, CS ;
Vetro, JA ;
Tomalia, DA ;
Koe, GS ;
Koe, JG ;
Middaugh, CR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (02) :423-436
[5]   Progress in antisense technology [J].
Crooke, ST .
ANNUAL REVIEW OF MEDICINE, 2004, 55 :61-95
[6]   Polyester dendritic systems for drug delivery applications:: In vitro and in vivo evaluation [J].
De Jesús, OLP ;
Ihre, HR ;
Gagne, L ;
Fréchet, JMJ ;
Szoka, FC .
BIOCONJUGATE CHEMISTRY, 2002, 13 (03) :453-461
[7]   Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery [J].
DeLong, R ;
Stephenson, K ;
Loftus, T ;
Fisher, M ;
Alahari, S ;
Nolting, A ;
Juliano, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (06) :762-764
[8]   siRNAs: Applications in functional genomics and potential as therapeutics [J].
Dorsett, Y ;
Tuschl, T .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :318-329
[9]   Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications [J].
Esfand, R ;
Tomalia, DA .
DRUG DISCOVERY TODAY, 2001, 6 (08) :427-436
[10]   Membrane-permeable arginine-rich peptides and the translocation mechanisms [J].
Futaki, S .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (04) :547-558